Compare iShares MSCI Japan ETF (EWJ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Japan ETF trades at $97.39 (market cap $23.87B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: iShares MSCI Japan ETF is the larger of the two by market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWJ | NBIX | |
|---|---|---|
Market Cap | $23.87B | $14.36B |
Volume | 5,412,820 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $185.50 |
52-Week Low | $78.36 | $123.10 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $98.32, down 1.01% on the day amid broader Asian market pressures. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. Recent news highlights Japan's monetary policy shifts with BOJ rate hikes and yen volatility creating both opportunities and challenges for Japanese equities. The ETF has demonstrated strong performance in 2026, outperforming the S&P 500 with gains exceeding 20% according to Zacks Investment Research (September 30, 2026).
The outlook for EWJ remains constructive given Japan's economic reforms and AI sector growth, though rising bond yields and currency fluctuations present near-term headwinds. Institutional interest appears strong as Japan's market rotation toward technology and AI plays supports continued ETF inflows. Key risks include BOJ policy uncertainty and global interest rate dynamics that could pressure Japanese equities.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
